Abstract: Disclosed herein is pharmaceutical compositions of Compound 1, and/or the hydroquinone form thereof, and methods useful for treating or suppressing a disease or disorder such as an ?-synucleinpathy, a tauopathy, an autistic spectrum disorder, a pervasive developmental disorder, a liver disease, and liver damage in a subject using such pharmaceutical compositions.

Abstract: The present description relates to a tablet formulation of 2-[3-(2,2,6,6-tetramethylpiperidin-4-yl)-3H-[1,2,3]triazolo[4,5-c]pyridazin-6-yl]-5-(2H-1,2,3-triazol-2-yl)phenol, a compound for use in treating Huntington's disease, and a method of making the same.

Abstract: Disclosed are a semiconductor structure and method of forming the structure. The structure has a semiconductor layer. A gate structure is located on the semiconductor layer. The gate structure has a sidewall spacer having a first section on the semiconductor layer and positioned laterally adjacent to the gate structure and further having a second section above and wider than the first section and positioned laterally adjacent the gate structure. A source/drain region is on the semiconductor layer and positioned laterally adjacent to the first section and the second section of the sidewall spacer.

Abstract: Disclosed herein is pharmaceutical compositions of Compound 1, and/or the hydroquinone form thereof, and methods useful for treating or suppressing a disease or disorder such as an ?-synucleinpathy, a tauopathy, an autistic spectrum disorder, a pervasive developmental disorder, a liver disease, and liver damage in a subject using such pharmaceutical compositions.

Abstract: An administration system for delivery of a pharmaceutical composition to a patient has a delivery device configured to deliver a dose of the pharmaceutical composition to the patient and a notification device in communication with the delivery device. The notification device is configured to communicate information about a status of at least one property of the delivery device. The delivery device can be a wearable automatic injector configured to be worn on the patient's skin. The delivery device of the present disclosure may allow a user or the patient to view a status of a container. For example, the delivery device of the present disclosure may provide a simple and effective visual means of displaying fill confirmation and delivery confirmation.

Abstract: An administration system for delivery of a pharmaceutical composition to a patient has a delivery device configured to deliver a dose of the pharmaceutical composition to the patient and a notification device in communication with the delivery device. The notification device is configured to communicate information about a status of at least one property of the delivery device. The delivery device can be a wearable automatic injector configured to be worn on the patient's skin. The delivery device of the present disclosure may allow a user or the patient to view a status of a container. For example, the delivery device of the present disclosure may provide a simple and effective visual means of displaying fill confirmation and delivery confirmation.

Abstract: Disclosed herein is pharmaceutical compositions of Compound 1, and/or the hydroquinone form thereof, and methods useful for treating or suppressing a disease or disorder such as an ?-synucleinpathy, a tauopathy, an autistic spectrum disorder, a pervasive developmental disorder, a liver disease, and liver damage in a subject using such pharmaceutical compositions.

Abstract: The present description generally relates to amorphous forms of compounds having enhanced aqueous solubility and dissolution rates and amorphous solid dispersions and oral pharmaceutical formulations thereof, and to processes for preparing the same. The present description specifically relates to amorphous forms of 5-fluoro-2-(6-fluoro-2-methyl-1H-benzimidazol-1-yl)-N-[4-(trifluoromethyl)phenyl]pyrimidine-4,6-diamine and amorphous solid dispersions and oral pharmaceutical formulations thereof, and to processes for preparing the same.

Abstract: The present description generally relates to a dispersible tablet composition of an active pharmaceutical ingredient (API), which rapidly disperses in water to provide a homogeneous dispersion that ensures uniformity of dose.

Abstract: The invention relates to bioavailable pharmaceutical compositions having increased dose loading and improved dissolution less subject to a food effect.

Abstract: An administration system for delivery of a pharmaceutical composition to a patient has a delivery device configured to deliver a dose of the pharmaceutical composition to the patient and a notification device in communication with the delivery device. The notification device is configured to communicate information about a status of at least one property of the delivery device. The delivery device is a wearable automatic injector configured to be worn on the patient's skin. A delivery device of the present disclosure allows a user or patient to view the status of a container. For example, a delivery device of the present disclosure provides a simple and effective visual means of displaying fill confirmation and delivery confirmation.

Abstract: A redundancy system for a steering system having a primary controller and a primary power source is provided. The redundancy system may include a secondary controller coupled to a secondary power source and configured to manage control of the steering system, and an interface circuit disposed between at least a first node and a second node. The first node may be in electrical communication with the primary power source, and the second node may be in electrical communication with the secondary power source. The interface circuit may be configured to selectively engage a self-test of the primary power source and the secondary power source, isolate a short at the first node from the secondary power source, and isolate a short at the second node from the primary power source.

Abstract: A redundancy system for a steering system having a primary controller and a primary power source is provided. The redundancy system may include a secondary controller coupled to a secondary power source and configured to manage control of the steering system, and an interface circuit disposed between at least a first node and a second node. The first node may be in electrical communication with the primary power source, and the second node may be in electrical communication with the secondary power source. The interface circuit may be configured to selectively engage a self-test of the primary power source and the secondary power source, isolate a short at the first node from the secondary power source, and isolate a short at the second node from the primary power source.

Abstract: An apparatus and method for performing a function on a terminal according to a received audio command are provided. The method includes receiving an audio command, determining a command target based on the audio command, and performing a function associated with the command target.

Abstract: The present invention relates to valacyclovir formulations having improved bioavailability resulting in better efficacy and/or requiring less frequent administration.

Abstract: A welding torch (10) for gas tungsten arc (tungsten inert gas) welding includes a housing (12) and an electrode holder (50, 52) which is mounted on the housing so as to project therefrom, and which is adapted to hold an electrode (54) such that the electrode projects from an end of the holder remote from the housing. A shroud (14) is mounted on, or forms part of, the housing (12) and extends around but is spaced from the electrode holder (50, 52). Electrically conductive means (46, 48) extends within the housing (12) for electrically connecting the electrode holder (50, 52) to one terminal of an electric power source. The torch (10) is adapted for connection to a source of an inert gas for generating a flow of gas through the shroud (14), around the electrode holder (50, 52).

Abstract: A locking device is disclosed, comprising a locking mechanism having a locked position and an unlocked position, a hollow plunger member having a central axis, the hollow plunger member being engaged with the locking mechanism to move the locking mechanism alternatively into the locked and unlocked positions upon reciprocating linear motion of the hollow plunger member in first and second directions along its central axis, and a motor having a shaft disposed coaxial with the central axis of the hollow plunger member is disclosed. In one embodiment, the locking device further comprises a spring having first and second ends, the first end being fixed to the motor shaft, and a pin fixed to the hollow plunger member for engaging the second end of the spring such that when the motor shaft rotates in a third direction the hollow plunger member moves in the first direction and when the motor shaft rotates in a fourth direction the hollow plunger member moves in the second direction.